Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VIPR2 | P41587 | 6/20 | 0.62 |
| ▸ | VIPR1 | P32241 | 5/20 | 0.62 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.57 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.57 |
| ▸ | GLP1R | P43220 | 3/20 | 0.56 |
| ▸ | CALCR | P30988 | 3/20 | 0.56 |
| ▸ | CCKBR | P32239 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.56 |
| ▸ | PTH1R | Q03431 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29742728 | 0.92 | VIPR2 (0.57) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| SCHEMBL30387584 | 0.91 | GLP1R (0.65) | GLP1RCALCRCCKBRKEAP1PTH1R | |
| Aviptadil SCHEMBL30969141 | 0.91 | VIPR1 (0.72) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| Vasoactive Intestinal Peptide SCHEMBL3041046 | 0.91 | VIPR1 (0.72) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| SCHEMBL31332028 | 0.90 | VIPR2 (0.66) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| SCHEMBL30567760 | 0.90 | VIPR1 (0.67) | VIPR2VIPR1GLP1R | |
| SCHEMBL31182706 | 0.90 | VIPR2 (0.56) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| SCHEMBL31331832 | 0.90 | VIPR1 (0.68) | VIPR2VIPR1CRHR1CRHR2GLP1R | |
| SCHEMBL29520076 | 0.90 | GLP1R (0.67) | GLP1RCALCRCCKBRKEAP1PTH1R | |
| SCHEMBL30607297 | 0.90 | VIPR2 (0.60) | VIPR2VIPR1CRHR1CRHR2GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465594-B2 | Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder | BROWN UNIVERSITY (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2025128794-A1 | FATTY ACID CONJUGATED CYCLIC PEPTIDES | NEUROCRINE BIOSCIENCES, INC. (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20240066009-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | Sanford Burnham Prebys Medical Discovery Institute | 2024-02-29 | — | — | US | disclosed |
| US-20240033258-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE (US) | 2024-02-01 | — | — | US | disclosed |
| US-20220273625-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | Sanford Burnham Prebys Medical Discovery Institute | 2022-09-01 | — | — | US | disclosed |
| US-20220202791-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL & MECHANICAL COLLEGE | 2022-06-30 | — | — | US | disclosed |
| US-11278527-B2 | Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder | BROWN UNIVERSITY (US) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273625-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | CRHBP, GRIN2C, GRIN2B | VIPR2 99/4885VIPR1 258/4885CRHR1 11/4885 |
| US-20240066009-A1 | COMPOSITIONS AND METHODS FOR THE MODULATION OF THE CORTICOTROPIN RELEASING FACTOR BINDING PROTEIN AND THE TREATMENT OF ALCOHOL USE DISORDER | CRHBP, GRIN2C, GRIN2B | VIPR2 98/4885VIPR1 266/4885CRHR1 12/4885 |
| US-12465594-B2 | Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder | CRHBP, GRIN2C, GRIN2B | VIPR2 98/4885VIPR1 266/4885CRHR1 12/4885 |
| US-11278527-B2 | Compositions and methods for the modulation of the corticotropin releasing factor binding protein and the treatment of alcohol use disorder | CRHBP, GRIN2C, GRIN2B | VIPR2 98/4885VIPR1 266/4885CRHR1 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.